Molecular predictors of metastasis in patients with prostate cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Schymura MJ, Sun L, Percy-Laurry A. Prostate cancer collaborative stage data items-their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010. Cancer-Am Cancer Soc. 2014;120(23):3758–3770.
   Google Scholar
• Chinese guidelines for diagnosis and treatment of prostate cancer. 2018 (English version). Chin J Cancer Res. 2019;31(1):67–83.
   PubMedGoogle Scholar
• Evans AJ. Treatment effects in prostate cancer. Modern Pathol. 2018;31:S110–S121.
   PubMed Web of Science ®Google Scholar
• Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized Phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080–1087.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA. 2015;314(1):80–82.
   PubMed Web of Science ®Google Scholar
• Boeve L, Hulshof MCCM, Verhagen PCMS, et al. Patient-reported quality of life in patients with primary metastatic prostate cancer treated with androgen deprivation therapy with and without concurrent radiation therapy to the prostate in a prospective randomised clinical trial; data from the HORRAD trial. Eur Urol. 2021;79(2):188–197.
   PubMed Web of Science ®Google Scholar
• Okamoto K. Prostate cancer with nodular bladder invasion (stage T4N1) cured by low-dose-rate brachytherapy with seminal vesicle implantation in combination with external beam radiotherapy of biologically effective dose ≥ 220 Gy: a case report. J Contemp Brachytherapy. 2021;13(1):91–94.
   PubMedGoogle Scholar
• Okayasu M, Takahashi H, Yamamoto T, et al. Stratification of seminal vesicle invasion as prognostic factors in prostate cancer. Lab Invest. 2013;93:238A–238A.
   Google Scholar
• Bernhardt J, Letzkus C, Kind M, et al. [Metastasis of prostate carcinoma to the lamina submucosa of the distal rectum in ulcerative colitis 2 years after transrectal prostate biopsy and radical prostatovesiculectomy]. Urologe A. 2005;44(1):64–67.
   PubMedGoogle Scholar
• Chen -J-J, Zhu Z-S, Zhu -Y-Y, et al. Applied anatomy of pelvic lymph nodes and its clinical significance for prostate cancer: a single-center cadaveric study. BMC CANCER. 2020;20(1):330.
   PubMedGoogle Scholar
• Onal C, Ozyigit G, Oymak E, et al. Clinical parameters and nomograms for predicting lymph node metastasis detected with 68 Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy. The Prostate. 2021;81(10):648–656.
   PubMedGoogle Scholar
• Amelot A, Terrier LM, Le Nail LR, et al. Spine metastasis in patients with prostate cancer: survival prognosis assessment. Prostate. 2021;81(2):91–101.
   PubMedGoogle Scholar
• Patra A, Khasawneh H, Suman G, et al. Atypical metastases in the abdomen and pelvis from biochemically recurrent prostate cancer: c-11-Choline PET/CT with multimodality correlation. Am J Roentgenol. 2022;218(1):141–150.
   PubMedGoogle Scholar
• Ulaner GA, Thomsen B, Bassett J, et al. 18F-DCFPyL PET/CT for initially diagnosed and biochemically recurrent prostate cancer: prospective trial with pathologic confirmation. Radiology. 2022;305(2):220218–220218.
   Google Scholar
• Lander RD, O’Donnell MJ. A case of metastatic prostate cancer to the distal phalanx. Hand (N Y). 2022;17(3):1–4.
   Google Scholar
• Nabih O, Mtalai N, El Maaloum L, et al. Orbital metastases from prostate adenocarcinoma: case report and review of the literature. Ann Med Surg. 2022;76(2012):103530–103530.
   PubMedGoogle Scholar
• Akagi N, Oshima K, Fukui K, et al. Castration-resistant prostate cancer with metastasis to external auditory canal - Case report. Urol Case Rep. 2022;44:102141–102141.
   PubMedGoogle Scholar
• Ahuja US, Shetty DC, Rathore A, et al. Occult prostate carcinoma with metastasis to the mandible presenting as numb chin syndrome. J Oral Biol Craniofac Res. 2021;11(3):393–395.
   PubMedGoogle Scholar
• Kosaka T, Iizuka S, Yoneda T, et al. Solitary pulmonary nodule as the initial manifestation of isolated metastasis from prostate cancer without bone involvement: a case report. Int J Surg Case Rep. 2022;90:106681–106681.
   PubMedGoogle Scholar
• Alshalalfa M, Seldon C, Franco I, et al. Clinicogenomic characterization of prostate cancer liver metastases. Prostate Cancer Prostatic Dis. 2022;25(2):366–369.
   PubMedGoogle Scholar
• Rodriguez-Calero A, Gallon J, Akhoundova D, et al. Alterations in homologous recombination repair genes in prostate cancer brain metastases. Nat Commun. 2022;13(1): DOI:10.1038/s41467-022-30003-5
   PubMedGoogle Scholar
• Dulskas A, Cereska V, Zurauskas E, et al. Prostate cancer solitary metastasis to anal canal: case report and review of literature. BMC CANCER. 2019;19(1). DOI:10.1186/s12885-019-5573-9
   PubMedGoogle Scholar
• Saad F, McKiernan J, Eastham J. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. Urol Oncol: Semin Orig Investig. 2006;24(1):4–12.
   PubMedGoogle Scholar
• Wang G, Zhao D, DJ S, et al. Genetics and biology of prostate cancer. Genes Dev. 2018;32(17-18)(17–18):1105–1140.
   Google Scholar
• Lee RJ, Saylor PJ, Michaelson MD, et al. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res. 2013;19(11):3088–3094.
   PubMed Web of Science ®Google Scholar
• Kolb AA-O, Bussard KA-O. The bone extracellular matrix as an ideal milieu for cancer cell metastases. LID LID - 1020. (2072–6694 (Print))). DOI:10.3390/cancers11071020.
   Google Scholar
• Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–1228.
   PubMed Web of Science ®Google Scholar
• Jamaspishvili T, Patel PG, Niu Y, et al. Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN). J Natl Cancer Inst. 2020;112(11):1098–1104.
   PubMedGoogle Scholar
• Chen W, Xia W, Xue S, et al. Analysis of BRCA germline mutations in Chinese prostate cancer patients. Front Oncol. 2022;12:746102.
   PubMedGoogle Scholar
• Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443–453.
   PubMed Web of Science ®Google Scholar
• Goel S, Bhatia V, Kundu S, et al. Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression. Nat Commun. 2021;12(1). DOI:10.1038/s41467-021-25623-2.
   Google Scholar
• Blattner M, Liu DL, Robinson BD, et al. SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K/mTOR and AR signaling. Cancer Cell. 2017;31(3):436–451.
   PubMed Web of Science ®Google Scholar
• Hsieh CL, Botta G, Gao S, et al. PLZF, a tumor suppressor genetically lost in metastatic castration resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. Cancer Res. 2015;75(10):22.
   PubMedGoogle Scholar
• Ku SY, Rosario S, Wang YQ, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355(6320):78–83.
   PubMed Web of Science ®Google Scholar
• Limberger T, Schlederer M, Trachtova K, et al. KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis. Mol Cancer. 2022;21(1). DOI:10.1186/s12943-022-01542-8.
   Google Scholar
• Wu YM, Cieslik M, Lonigro RJ, et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell. 2018;173(7):1770–+.
   PubMed Web of Science ®Google Scholar
• Thysell E, Kohn L, Semenas J, et al. Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C. Mol Oncol. 2022;16(4):846–859.
   PubMedGoogle Scholar
• Gao Y, Bado I, Wang H, et al. Metastasis organotropism: redefining the congenial soil. Dev Cell. 2019;49(3):375–391.
   PubMed Web of Science ®Google Scholar
• Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239–243.
   PubMed Web of Science ®Google Scholar
• Quigley DA, Dang HX, Zhao SG, et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell. 2018;174(3):758–+.
   PubMed Web of Science ®Google Scholar
• Lin -B-B, Lei H-Q, Xiong H-Y, et al. MicroRNA-regulated transcriptome analysis identifies four major subtypes with prognostic and therapeutic implications in prostate cancer. Comput Struct Biotechnol J. 2021;19:4941–4953.
   PubMed Web of Science ®Google Scholar
• Fraser M, Livingstone J, Wrana JL, et al. Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse. Nat Commun. 2021;12(1). DOI:10.1038/s41467-021-26489-0.
   Google Scholar
• Tong DL. Unravelling the molecular mechanisms of prostate cancer evolution from genotype to phenotype. Crit Rev Oncol Hemat. 2021;163:103370.
   PubMedGoogle Scholar
• Zhao Y, Ding LY, Wane DJ, et al. EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. Embo J. 2019;38(5). DOI:10.15252/embj.201899599.
   Web of Science ®Google Scholar
• Humid AA, Gray KP, Shaw G, et al. Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer. Eur Urol. 2019;76(1):89–97.
   PubMedGoogle Scholar
• Mei WJ, Lin XZ, Kapoor A, et al. The contributions of prostate cancer stem cells in prostate cancer initiation and metastasis. Cancers (Basel). 2019;11(4):434.
   PubMedGoogle Scholar
• Nombela P, Lozano R, Aytes A, et al. BRCA2 and other DDR genes in prostate cancer. Cancers (Basel). 2019;11(3):352.
   PubMed Web of Science ®Google Scholar
• Chakraborty G, Armenia J, Mazzu YZ, et al. Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression. Clin Cancer Res. 2020;26(8):2047–2064.
   PubMed Web of Science ®Google Scholar
• Cheng L, Nagabhushan M, Pretlow TP, et al. Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol. 1996;148(5):1375–1380.
   PubMed Web of Science ®Google Scholar
• Kolijn K, Verhoef EI, Smid M, et al. Epithelial-mesenchymal transition in human prostate cancer demonstrates enhanced immune evasion marked by IDO1 expression. Cancer Res. 2018;78(16):4671–4679.
   PubMedGoogle Scholar
• Zhang K, Guo Y, Wang X, et al. WNT/beta-catenin directs self-renewal symmetric cell division of hTERT(high) prostate cancer stem cells. Cancer Res. 2017;77(9):2534–2547.
   PubMedGoogle Scholar
• Ratnayake WS, Apostolatos CA, Breedy S, et al. Atypical PKCs activate Vimentin to facilitate prostate cancer cell motility and invasion. Cell Adhes Migr. 2021;15(1):37–57.
   PubMed Web of Science ®Google Scholar
• Lee Y, Yoon J, Ko D, et al. TMPRSS4 promotes cancer stem-like properties in prostate cancer cells through upregulation of SOX2 by SLUG and TWIST1. J Exp Clin Canc Res. 2021;40(1). DOI:10.1186/s13046-021-02147-7
   Google Scholar
• Wang Z, Hulsurkar M, Zhuo LJ, et al. CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation. Neoplasia. 2021;23(11):1147–1165.
   PubMedGoogle Scholar
• Cai G, Wu D, Wang Z, et al. Collapsin response mediator protein-1 (CRMP1) acts as an invasion and metastasis suppressor of prostate cancer via its suppression of epithelial-mesenchymal transition and remodeling of actin cytoskeleton organization. Oncogene. 2017;36(4):546–558.
   PubMedGoogle Scholar
• Martinez-Martinez D, Lobo MVT, Baquero P, et al. Downregulation of snail by DUSP1 impairs cell migration and invasion through the inactivation of JNK and ERK and is useful as a predictive factor in the prognosis of prostate cancer. Cancers (Basel). 2021;13(5). DOI:10.3390/cancers13051158.
   PubMedGoogle Scholar
• Sun YX, Wang JC, Shelburne CE, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem. 2003;89(3):462–473.
   PubMedGoogle Scholar
• Balasubramaniam S, Comstock CES, Ertel A, et al. Aberrant BAF57 signaling facilitates prometastatic phenotypes. Clin Cancer Res. 2013;19(10):2657–2667.
   PubMed Web of Science ®Google Scholar
• Bamodu OA, Wang Y-H, Ho C-H, et al. Genetic suppressor element 1 (GSE1) promotes the oncogenic and recurrent phenotypes of castration-resistant prostate cancer by targeting tumor-associated calcium signal transducer 2 (TACSTD2). Cancers (Basel). 2021;13(16):3959.
   PubMedGoogle Scholar
• Chen WY, Tsai YC, Siu MK, et al. Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis. Oncogene. 2017;36(45):6213–6224.
   PubMedGoogle Scholar
• Tsai YC, Chen WY, Abou-Kheir W, et al. Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2. Bba-Mol Basis Dis. 2018;1864(5):1717–1727.
   PubMedGoogle Scholar
• Vanli N, Sheng JH, Li SP, et al. Ribonuclease 4 is associated with aggressiveness and progression of prostate cancer. Commun Biol. 2022;5(1). DOI:10.1038/s42003-022-03597-1
   PubMedGoogle Scholar
• Jimenez-Vacas JM, Herrero-Aguayo V, Gomez-Gomez E, et al. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. Transl Res. 2019;212:89–103.
   PubMedGoogle Scholar
• Ye JW, Gao MQ, Guo XW, et al. Breviscapine suppresses the growth and metastasis of prostate cancer through regulating PAQR4-mediated PI3K/Akt pathway. Biomed Pharmacother. 2020;127:110223.
   PubMedGoogle Scholar
• Xiao ZM, Lv DJ, Yu YZ, et al. SMARCC1 suppresses tumor progression by inhibiting the PI3K/AKT signaling pathway in prostate cancer. Front Cell Dev Biol. 2021;9. DOI:10.3389/fcell.2021.678967.
   Google Scholar
• Li JF, Xie HY, Ying YF, et al. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer. Mol Cancer. 2020;19(1). DOI:10.1186/s12943-020-01267-6.
   Google Scholar
• Zhang AY, Chiam K, Haupt Y, et al. An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. Int J Cancer. 2019;144(5):1151–1159.
   PubMedGoogle Scholar
• Luo ZZ, Wang J, Zhu Y, et al. SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway. Neoplasia. 2021;23(10):1037–1047.
   PubMedGoogle Scholar
• Chen Q, Wan X, Chen YB, et al. SGO1 induces proliferation and metastasis of prostate cancer through AKT-mediated signaling pathway. Am J Cancer Res. 2019;9(12):2693–+.
   PubMedGoogle Scholar
• Li T, Yu Y, Song YR, et al. Activation of BDNF/TrkB pathway promotes prostate cancer progression via induction of epithelial-mesenchymal transition and anoikis resistance. Faseb J. 2020;34(7):9087–9101.
   PubMedGoogle Scholar
• Peng SM, Chen X, Huang CY, et al. UBE2S as a novel ubiquitinated regulator of p16 and beta-catenin to promote bone metastasis of prostate cancer. Int J Biol Sci. 2022;18(8):3528–3543.
   PubMedGoogle Scholar
• Pan KA-O, Lee WJ, Chou CC, et al. Direct interaction of β-catenin with nuclear ESM1 supports stemness of metastatic prostate cancer. The EMBO journal. 2021;40(4):e105450.
   PubMedGoogle Scholar
• Qi M, Hu J, Cui Y, et al. CUL4B promotes prostate cancer progression by forming positive feedback loop with SOX4. ONCOGENESIS. 2019;8(3). DOI:10.1038/s41389-019-0131-5.
   Google Scholar
• Wang L, Wang JY, Yin XL, et al. GIPC2 interacts with Fzd7 to promote prostate cancer metastasis by activating WNT signaling. Oncogene. 2022;41(18):2609–2623.
   PubMedGoogle Scholar
• Esposito MA-O, Fang C, Cook KA-O, et al. TGF-β-induced DACT1 biomolecular condensates repress Wnt signalling to promote bone metastasis. Nature cell biology. 2021;23(3): 257–267.
   PubMedGoogle Scholar
• Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697–1708.
   PubMed Web of Science ®Google Scholar
• Yu HB, Xu Z, Guo MM, et al. FOXM1 modulates docetaxel resistance in prostate cancer by regulating KIF20A. Cancer Cell Int. 2020;20(1). DOI:10.1186/s12935-020-01631-y.
   Google Scholar
• Yang L, Jin ML, Park SJ, et al. SETD1A promotes proliferation of castration-resistant prostate cancer cells via FOXM1 transcription. Cancers (Basel). 2020;12(7):1736.
   PubMedGoogle Scholar
• Wen SM, Wei YL, Zen C, et al. Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine. Mol Cancer. 2020;19(1). DOI:10.1186/s12943-020-01293-4
   Google Scholar
• Zou LB, Chen WB, Zhou XM, et al. N6-methyladenosine demethylase FTO suppressed prostate cancer progression by maintaining CLIC4 mRNA stability. Cell Death Discov. 2022;8(1). DOI:10.1038/s41420-022-01003-7.
   Google Scholar
• Zhao Y, Hu X, Yu HR, et al. Alternations of gene expression in PI3K and AR pathways and DNA methylation features contribute to metastasis of prostate cancer. Cell Mol Life Sci. 2022;79(8). DOI:10.1007/s00018-022-04456-2
   Google Scholar
• Aytes A, Giacobbe A, Mitrofanova A, et al. NSD2 is a conserved driver of metastatic prostate cancer progression. Nat Commun. 2018;9(1). DOI:10.1038/s41467-018-07511-4.
   PubMedGoogle Scholar
• Fan LL, Zhang FB, Xu SH, et al. Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells. Proc Natl Acad Sci U S A. 2018;115(20):E4584–E4593.
   PubMedGoogle Scholar
• Kim TD, Jin F, Shin S, et al. Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1. J Clin Invest. 2016;126(2):706–720.
   PubMed Web of Science ®Google Scholar
• Yuan PH, Ling L, Gao XT, et al. Identification of RNA-binding protein SNRPA1 for prognosis in prostate cancer. Aging-Us. 2021;13(2):2895–2911.
   Google Scholar
• Jacob S, Nayak S, Fernandes G, et al. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer. Endocr Relat Cancer. 2014;21(3):473–486.
   PubMedGoogle Scholar
• Hoflmayer D, Steinhoff A, Hube-Magg C, et al. Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer. Mol Oncol. 2020;14(1):129–138.
   PubMedGoogle Scholar
• Reis ST, Pontes-Júnior J, Fau - Antunes AA, et al. Tgf-β1 expression as a biomarker of poor prognosis in prostate cancer. Clinics (Sao Paulo, Brazil). 2011;66(7):1143–1147.
   PubMed Web of Science ®Google Scholar
• Fournier PGJ, Juarez P, Jiang GL, et al. The TGF-beta signaling regulator PMEPA1 suppresses prostate cancer metastases to bone. Cancer Cell. 2015;27(6):809–821.
   PubMed Web of Science ®Google Scholar
• Her NG, Jeong S, Fau - Cho K, et al. PPARδ promotes oncogenic redirection of TGF-β1 signaling through the activation of the ABCA1-Cav1 pathway. Cell Cycle. 2013;12(10):1521–1535.
   PubMed Web of Science ®Google Scholar
• Mishra S, Tang Y, Fau - Wang L, et al. Blockade of transforming growth factor-beta (TGFβ) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line. Prostate. 2011;71(13):1441–1454.
   PubMedGoogle Scholar
• Hu J, Tian J, Zhu S, et al. Sox5 contributes to prostate cancer metastasis and is a master regulator of TGF-β-induced epithelial mesenchymal transition through controlling Twist1 expression. British journal of cancer. 2018;118(1):88–97.
   PubMedGoogle Scholar
• Shi Z, Xiao C, Lin T, et al. BZW1 promotes cell proliferation in prostate cancer by regulating TGF-β1/Smad pathway. Cell Cycle. 2021;20(9):894–902.
   PubMedGoogle Scholar
• Kwon W, Choi SK, Kim D, et al. ZNF507 affects TGF-beta signaling via TGFBR1 and MAP3K8 activation in the progression of prostate cancer to an aggressive state. J Exp Clin Canc Res. 2021;40(1). DOI:10.1186/s13046-021-02094-3.
   Google Scholar
• Liu X, Chen L, Fan YH, et al. IFITM3 promotes bone metastasis of prostate cancer cells by mediating activation of the TGF-beta signaling pathway. Cell Death Dis. 2019;10(7). DOI:10.1038/s41419-019-1750-7.
   Google Scholar
• Thapa DA-O, Huang SA-O, Muñoz AA-O, et al. Attenuation of NAD[P]H: quinone oxidoreductase 1 aggravates prostate cancer and tumor cell plasticity through enhanced TGFβ signaling. Communications biology. 2020;3:12. DOI:10.1038/s42003-019-0720-z.
   PubMedGoogle Scholar
• Lin H-Y, Ko C-J, Lo T-Y, et al. Matriptase-2/NR4A3 axis switches TGF-β action toward suppression of prostate cancer cell invasion, tumor growth, and metastasis. ONCOGENE. 2022;41(20):2833–2845.
   PubMedGoogle Scholar
• Yan YW, Zhou B, Qian C, et al. Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis. Nat Commun. 2022;13(1):669.
   PubMed Web of Science ®Google Scholar
• Qiu J, Yang B. MAGE-C2/CT10 promotes growth and metastasis through upregulating c-Myc expression in prostate cancer. Mol Cell Biochem. 2021;476(1):1–10.
   PubMedGoogle Scholar
• Luo P, Jiang Q, Fang Q, et al. The human positive cofactor 4 promotes androgen-independent prostate cancer development and progression through HIF-1 alpha/beta-catenin pathway. Am J Cancer Res. 2019;9(4):682–+.
   PubMedGoogle Scholar
• Kaminski L, Torrino S, Dufies M, et al. PGC1 alpha inhibits polyamine synthesis to suppress prostate cancer aggressiveness. Cancer Res. 2019;79(13):3268–3280.
   PubMedGoogle Scholar
• Hsu E-C, Rice MA, Bermudez A, et al. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proc Natl Acad Sci U S A. 2020;117(4):2032–2042.
   PubMedGoogle Scholar
• Vecchiotti D, Verzella D, Nolfi MDV, et al. Elevated NF-kappa B/SHh/GLI1 signature denotes a worse prognosis and represent a novel potential therapeutic target in advanced prostate cancer. CELLS. 2022;11(13):2118.
   PubMedGoogle Scholar
• Jung AR, Kim GE, Kim MY, et al. HMGB1 promotes tumor progression and invasion through HMGB1/TNFR1/NF-kappa B axis in castration-resistant prostate cancer. Am J Cancer Res. 2021;11(5):2215–+.
   PubMedGoogle Scholar
• Xu BH, Shi F, Feng YQ. Inhibition of ubiquitin specific protease 17 restrains prostate cancer proliferation by regulation of epithelial-to-mesenchymal transition (EMT) via ROS production. Biomed Pharmacother. 2019;118:108946.
   PubMedGoogle Scholar
• Fu Q, Gao Y, Yang F, et al. Suppression of microRNA-454 impedes the proliferation and invasion of prostate cancer cells by promoting N-myc downstream-regulated gene 2 and inhibiting WNT/beta-catenin signaling. Biomed Pharmacother. 2018;97:120–127.
   PubMed Web of Science ®Google Scholar
• Zhu ZG, Luo LM, Xiang Q, et al. MiRNA-671-5p promotes prostate cancer development and metastasis by targeting NFIA/CRYAB axis. Cell Death Dis. 2020;11(11). DOI:10.1038/s41419-020-03138-w.
   Google Scholar
• Bonci D, Coppola V, Musumeci M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14(11):1271–1277.
   PubMed Web of Science ®Google Scholar
• Ren D, Yang Q, Dai Y, et al. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-kappa B signaling pathway. Mol Cancer. 2017;16(1). DOI:10.1186/s12943-017-0688-6.
   Google Scholar
• Liu YZ, Zhao SK, Wang JM, et al. MiR-629-5p promotes prostate cancer development and metastasis by targeting AKAP13. Front Oncol. 2021;11:754353.
   PubMedGoogle Scholar
• Dai YP, Gao XQ. Inhibition of cancer cell-derived exosomal microRNA-183 suppresses cell growth and metastasis in prostate cancer by upregulating TPM1. Cancer Cell Int. 2021;21(1). DOI:10.1186/s12935-020-01686-x
   Google Scholar
• Ren D, Wang M, Gu W, et al. Wild-type p53 suppresses the epithelial-mesenchymal transition and sternness in PC-3 prostate cancer cells by modulating miR-145. Int J Oncol. 2013;42(4):1473–1481.
   PubMedGoogle Scholar
• Huang S, Wa Q, Pan J, et al. Downregulation of miR-141-3p promotes bone metastasis via activating NF-kappa B signaling in prostate cancer. J Exp Clin Canc Res. 2017;36(1). DOI:10.1186/s13046-017-0645-7.
   Google Scholar
• Wa Q, Huang S, Pan J, et al. miR-204-5p represses bone metastasis via inactivating NF-kappa B signaling in prostate cancer. Molecular Therapy - Nucleic Acids. 2019;18:567–579.
   Google Scholar
• Wa Q, Zou C, Lin Z, et al. Ectopic expression of miR-532-3p suppresses bone metastasis of prostate cancer cells via inactivating NF-kappa B signaling. Molecular Therapy - Oncolytics. 2020;17:267–277.
   PubMed Web of Science ®Google Scholar
• Rajendiran S, Parwani AV, Hare RJ, et al. MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1. Mol Cancer. 2014;13(1). DOI:10.1186/1476-4598-13-250
   PubMedGoogle Scholar
• Fang L-L, Sun B-F, Huang L-R, et al. Potent inhibition of miR-34b on migration and invasion in metastatic prostate cancer cells by regulating the TGF-beta pathway. Int J Mol Sci. 2017;18(12):2762.
   PubMed Web of Science ®Google Scholar
• Dai YH, Wu ZQ, Lang CD, et al. Copy number gain of ZEB1 mediates a double-negative feedback loop with miR-33a-5p that regulates EMT and bone metastasis of prostate cancer dependent on TGF-beta signaling. Theranostics. 2019;9(21):6063–6079.
   PubMed Web of Science ®Google Scholar
• Bucay N, Bhagirath D, Sekhon K, et al. A novel microRNA regulator of prostate cancer epithelial-mesenchymal transition. Cell Death Differ. 2017;24(7):1263–1274.
   PubMed Web of Science ®Google Scholar
• Fu QZ, Liu XF, Liu Y, et al. MicroRNA-335 and-543 suppress bone metastasis in prostate cancer via targeting endothelial nitric oxide synthase. Int J Mol Med. 2015;36(5):1417–1425.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Duan Y, Wang P. SP1-mediated upregulation of lncRNA SNHG4 functions as a ceRNA for miR-377 to facilitate prostate cancer progression through regulation of ZIC5. J Cell Physiol. 2020;235(4):3916–3927.
   PubMed Web of Science ®Google Scholar
• Wang XB, Chen QJ, Wang X, et al. ZEB1 activated-VPS9D1-AS1 promotes the tumorigenesis and progression of prostate cancer by sponging miR-4739 to upregulate MEF2D. Biomed Pharmacother. 2020;122:109557.
   PubMed Web of Science ®Google Scholar
• Ren SC, Liu YW, Xu WD, et al. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol. 2013;190(6):2278–2287.
   PubMed Web of Science ®Google Scholar
• Zhang W, Shi XL, Chen R, et al. Novel long non-coding RNA lncAMPC promotes metastasis and immunosuppression in prostate cancer by stimulating LIF/LIFR expression. Mol Ther. 2020;28(11):2473–2487.
   PubMedGoogle Scholar
• Malik R, Patel L, Prensner JR, et al. The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. Mol Cancer Res. 2014;12(8):1081–1087.
   PubMed Web of Science ®Google Scholar
• Sakurai K, Reon BJ, Anaya J, et al. The lncRNA DRAIC/PCAT29 locus constitutes a tumor-suppressive nexus. Mol Cancer Res. 2015;13(5):828–838.
   PubMed Web of Science ®Google Scholar
• White NM, Zhao SG, Zhang J, et al. Multi-institutional analysis shows that low PCAT-14 expression associates with poor outcomes in prostate cancer. Eur Urol. 2017;71(2):257–266.
   PubMedGoogle Scholar
• Jin CJ, Zhao WM, Zhang ZJ, et al. Silencing circular RNA circZNF609 restrains growth, migration and invasion by up-regulating microRNA-186-5p in prostate cancer (Publication with Expression of Concern. See vol. 49, pg. 164, 2021). Artif Cell Nanomed B. 2019;47(1):3350–3358.
   PubMed Web of Science ®Google Scholar
• Huang CK, Deng HH, Wang YH, et al. Circular RNA circABCC4 as the ceRNA of miR-1182 facilitates prostate cancer progression by promoting FOXP4 expression. J Cell Mol Med. 2019;23(9):6112–6119.
   PubMed Web of Science ®Google Scholar
• Shan GY, Shao B, Liu Q, et al. circFMN2 sponges miR-1238 to promote the expression of LIM-homeobox gene 2 in prostate cancer cells. Mol Ther Nucleic Acids. 2020;21:133–146.
   PubMedGoogle Scholar
• Liu DC, Song LL, Li XZ, et al. Circular RNA circHIPK3 modulates prostate cancer progression via targeting miR-448/MTDH signaling. Clin Transl Oncol. 2021;23(12):2497–2506.
   PubMed Web of Science ®Google Scholar
• Wu G, Sun Y, Xiang ZD, et al. Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression. Cell Death Dis. 2019;10(2):37.
   PubMedGoogle Scholar
• Song ZY, Zhuo ZY, Ma Z, et al. Hsa_Circ_0001206 is downregulated and inhibits cell proliferation, migration and invasion in prostate cancer. Artificial Cells Nano Biotech. 2019;47(1):2449–2464.
   PubMed Web of Science ®Google Scholar
• Yang Z, Qu CB, Zhang Y, et al. Dysregulation of p53-RBM25-mediated circAMOTL1L biogenesis contributes to prostate cancer progression through the circAMOTL1L-miR-193a-5p-Pcdha pathway. Oncogene. 2019;38(14):2516–2532.
   PubMed Web of Science ®Google Scholar
• Montes MR, Calvo PA, Sanchez JAG. Small cell metastatic prostate cancer with ectopic adrenocorticotropic hormone hypersecretion: a case report. Ann Palliat Med. 2021;10(12):12911–12914.
   PubMedGoogle Scholar
• Lu XJ, Gao WW, Zhang Y, et al. Case report: systemic treatment and serial genomic sequencing of metastatic prostate adenocarcinoma progressing to small cell carcinoma. Front Oncol. 2021;11. DOI:10.3389/fonc.2021.732071.
   Google Scholar
• Zong Y, Montironi R, Massari F, et al. Intraductal carcinoma of the prostate: pathogenesis and molecular perspectives. Eur Urol Focus. 2021;7(5):955–963.
   PubMedGoogle Scholar
• Zhang CJ, Qian JQ, Wu YC, et al. Identification of novel diagnosis biomarkers for therapy-related neuroendocrine prostate cancer. Pathol Oncol Res. 2021;27. DOI:10.3389/pore.2021.1609968.
   Google Scholar
• Pedersen V, Petersen KS, Brasso K, et al. Basal cell carcinoma of prostate with MSMB-NCOA4 fusion and a probable basal cell carcinoma in situ: case report. Int J Surg Pathol. 2021;29(8):850–855.
   PubMedGoogle Scholar
• Miyai K, Divatia MK, Shen SS, et al. Clinicopathological analysis of intraductal proliferative lesions of prostate: intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion. Hum Pathol. 2014;45(8):1572–1581.
   PubMedGoogle Scholar
• Khani F, Wobker SE, Hicks JL, et al. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations. J Pathol. 2019;249(1):79–89.
   PubMedGoogle Scholar
• Kato M, Hirakawa A, Kobayashi Y, et al. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients. Prostate. 2020;80(3):284–290.
   PubMedGoogle Scholar
• Unno K, Chalmers ZR, Pamarthy S, et al. Activated ALK cooperates with N-Myc via Wnt/beta-Catenin signaling to induce neuroendocrine prostate cancer. Cancer Res. 2021;81(8):2157–2170.
   PubMedGoogle Scholar
• Singh N, Ramnarine VR, Song JH, et al. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021;12(1). DOI:10.1038/s41467-021-26901-9.
   Google Scholar
• Hsu EC, Shen M, Aslan M, et al. MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer. Sci Rep-Uk. 2021;11(1):13305.
   PubMedGoogle Scholar
• Vlachostergios PJ, Karathanasis A, Tzortzis V. Expression of fibroblast activation protein is enriched in neuroendocrine prostate cancer and predicts worse survival. Genes (Basel). 2022;13(1):135.
   PubMed Web of Science ®Google Scholar
• Yoo YA, Vatapalli R, Lysy B, et al. The role of castration-resistant Bmi1+Sox2+Cells in driving recurrence in prostate cancer. J Natl Cancer Inst. 2019;111(3):311–321.
   PubMedGoogle Scholar
• Yasumizu Y, Rajabi H, Jin CN, et al. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun. 2020;11(1):1095.
   PubMedGoogle Scholar
• Inoue K, Slaton JW, Eve BY, et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res. 2000;6(5):2104–2119.
   PubMed Web of Science ®Google Scholar
• Ribas J, Ni XH, Haffner M, et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009;69(18):7165–7169.
   PubMed Web of Science ®Google Scholar
• Mercatelli N, Coppola V, Bonci D, et al. The inhibition of the highly expressed Mir-221 and Mir-222 impairs the growth of prostate carcinoma xenografts in mice. Plos One. 2008;3(12):e4029.
   PubMed Web of Science ®Google Scholar
• Song XL, Huang B, Zhou BW, et al. miR-1301-3p promotes prostate cancer stem cell expansion by targeting SFRP1 and GSK3 beta. Biomed Pharmacother. 2018;99:369–374.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of Cancer: the Next Generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Shiao SL, Chu GCY, Chung LWK. Regulation of prostate cancer progression by the tumor microenvironment. Cancer Lett. 2016;380(1):340–348.
   PubMed Web of Science ®Google Scholar
• Boxler S, Djonov V, Kessler TM, et al. Matrix metalloproteinases and angiogenic factors predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer? Am J Pathol. 2010;177(5):2216–2224.
   PubMed Web of Science ®Google Scholar
• Qian YR, Liu XZ, Feng Y, et al. Tenascin C regulates cancer cell glycolysis and tumor progression in prostate cancer. Int J Urol. 2022;29(6):578–585.
   PubMedGoogle Scholar
• Jung YH, Kim JK, Shiozawa Y, et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun. 2013;4(1). DOI:10.1038/ncomms2766.
   Google Scholar
• Dahran N, Szewczyk-Bieda M, Vinnicombe S, et al. Periprostatic fat adipokine expression is correlated with prostate cancer aggressiveness in men undergoing radical prostatectomy for clinically localized disease. BJU Int. 2019;123(6):985–994.
   PubMedGoogle Scholar
• Laurent V, Guerard A, Mazerolles C, et al. Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity. Nat Commun. 2016;7(1). DOI:10.1038/ncomms10230.
   Google Scholar
• Huang RL, Wang SQ, Wang N, et al. CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating beta-catenin/STAT3 signaling. Cell Death Dis. 2020;11(4). DOI:10.1038/s41419-020-2435-y.
   Google Scholar
• Magnon C, Hall SJ, Lin J, et al. Autonomic nerve development contributes to prostate cancer progression. Science. 2013;341(6142):143.
   Google Scholar
• Warrington RJ, Lewis KE. Natural antibodies against nerve growth factor inhibit in vitro prostate cancer cell metastasis. Cancer Immunol Immun. 2011;60(2):187–195.
   PubMedGoogle Scholar
• Dobrenis K, Gauthier LR, Barroca V, et al. Granulocyte colony-stimulating factor off-target effect on nerve outgrowth promotes prostate cancer development. Int J Cancer. 2015;136(4):982–988.
   PubMed Web of Science ®Google Scholar
• Ban KC, Feng S, Shao LJ, et al. RET signaling in prostate cancer. Clin Cancer Res. 2017;23(16):4885–4896.
   PubMedGoogle Scholar
• Shen TY, Li Y, Zhu SM, et al. YAP1 plays a key role of the conversion of normal fibroblasts into cancer-associated fibroblasts that contribute to prostate cancer progression. J Exp Clin Canc Res. 2020;39(1). DOI:10.1186/s13046-020-1542-z.
   Google Scholar
• Hodolic M, Maffione AM, Fettich J, et al. Metastatic prostate cancer proven by F-18-FCH PET/CT staging scan in patient with normal PSA but high PSA doubling time. Clin Nucl Med. 2013;38(9):739–740.
   PubMedGoogle Scholar
• Gjertson CK, Albertsen PC. Use and assessment of PSA in prostate cancer. Med Clin North Am. 2011;95(1):191–+.
   PubMedGoogle Scholar
• Lorente D, Ravi P, Mehra N, et al. Interrogating metastatic prostate cancer treatment switch decisions: a multi-institutional survey. Eur Urol Focus. 2018;4(2):235–244.
   PubMedGoogle Scholar
• Sabur V, Untan I, Tatlisen A. Role of PSA kinetics in hormone-refractory prostate cancer. Jcpsp-J Coll Physici. 2021;31(6):673–678.
   Google Scholar
• Lonergan PE, Cowan JE, Washington SL, et al. Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort. Prostate. 2021;81(13):1009–1017.
   PubMedGoogle Scholar
• Miszczyk M, Magrowski L, Masri O, et al. Prostate-specific antigen kinetics and metastasis-free survival in patients treated with external beam radiotherapy combined with high-dose-rate brachytherapy boost and androgen deprivation therapy for localized prostate cancer. J Contemp Brachytherapy. 2022;14(1):15–22.
   PubMedGoogle Scholar
• Pellegrino F, Coghi A, Lavorgna G, et al. A mechanistic insight into the anti-metastatic role of the prostate specific antigen. Transl Oncol. 2021;14(11):101211.
   PubMedGoogle Scholar
• Stikbakke E, Richardsen E, Knutsen T, et al. Inflammatory serum markers and risk and severity of prostate cancer: the PROCA-life study. Int J Cancer. 2020;147(1):84–92.
   PubMedGoogle Scholar
• Yu MS, Yang CC, Wang S, et al. Serum ProGRP as a novel biomarker of bone metastasis in prostate cancer. Clin Chim Acta. 2020;510:437–441.
   PubMedGoogle Scholar
• Xie GS, Li G, Li Y, et al. Clinical association between pre-treatment levels of plasma fibrinogen and bone metastatic burden in newly diagnosed prostate cancer patients. Chinese Med J-Peking. 2019;132(22):2684–2689.
   PubMedGoogle Scholar
• Aufderklamm S, Hennenlotter J, Rausch S, et al. Oncological validation of bone turnover markers c-terminal telopeptide of type I collagen (1CTP) and peptides n-terminal propeptide of type I procollagen (P1NP) in patients with prostate cancer and bone metastases. Transl Androl Urol. 2021;10(10):4000–4008.
   PubMedGoogle Scholar
• Liu SQ, Shen M, Hsu EC, et al. Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer. Br J Cancer. 2021;124(5):896–900.
   PubMedGoogle Scholar
• Wallis CJD, Shayegan B, Morgan SC, et al. Prognostic association between common laboratory tests and overall survival in elderly men with de novo metastatic castration sensitive prostate cancer: a population-based study in Canada. Cancers (Basel). 2021;13(11):2844.
   PubMedGoogle Scholar
• Zhang M, Guan J, Huo YL, et al. Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy. Asian J Androl. 2019;21(4):387–392.
   PubMedGoogle Scholar
• Peng C, Juan C, Mao W, et al. Retrospective analysis of risk factors for bone metastasis in newly diagnosed prostate cancer patients. Eur Rev Med Pharmaco. 2022;26(11):3832–3839.
   PubMedGoogle Scholar
• de la Piedra C, Alcaraz A, Bellmunt J, et al. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study. Br J Cancer. 2013;108(12):2565–2572.
   PubMed Web of Science ®Google Scholar
• Une M, Takemura K, Inamura K, et al. Impact of serum gamma-glutamyltransferase on overall survival in men with metastatic castration-resistant prostate cancer treated with docetaxel. Cancers (Basel). 2021;13(21):5587.
   PubMedGoogle Scholar
• Blas L, Shiota M, Yamada S, et al. Lactate dehydrogenase is a serum prognostic factor in clinically regional lymph node-positive prostate cancer. Anticancer Res. 2021;41(8):3885–3889.
   PubMedGoogle Scholar
• Mak B, Lin HM, Kwan E, et al. Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. Asia-Pac J Clin Onco. 2021;17:48–49.
   PubMedGoogle Scholar
• Lin HM, Huynh K, Kohli M, et al. Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):860–870.
   PubMedGoogle Scholar
• Lin HM, Yeung NCL, Hastings JF, et al. Relationship between circulating lipids and cytokines in metastatic castration-resistant prostate cancer. Cancers (Basel). 2021;13(19):4964.
   PubMedGoogle Scholar
• Miro C, Di Giovanni A, Murolo M, et al. Thyroid hormone and androgen signals mutually interplay and enhance inflammation and tumorigenic activation of tumor microenvironment in prostate cancer. Cancer Lett. 2022;532:215581.
   PubMedGoogle Scholar
• Lucien F, Kim Y, Qian J, et al. Tumor-derived extracellular vesicles predict clinical outcomes in oligometastatic prostate cancer and suppress antitumor immunity. Int J Radiat Oncol Biol Phys. 2022;114(4):725–737.
   PubMedGoogle Scholar
• Wang C, Zhang ZC, Chong WL, et al. Improved prognostic stratification using circulating tumor cell clusters in patients with metastatic castration-resistant prostate cancer. Cancers (Basel). 2021;13(2):268.
   PubMedGoogle Scholar
• Antonarakis ES, Lu CX, Luber B, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration- resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J clin oncol. 2017;35(19):2149–+.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Zappavigna S, Crocetto F, et al. Assessment of total, PTEN-, and AR-V7(+) circulating tumor cell count by flow cytometry in patients with metastatic castration-resistant prostate cancer receiving enzalutamide. Clin Genitourin Canc. 2021;19(5):E286–E298.
   PubMedGoogle Scholar
• Yang YJ, Liu Z, Wang QF, et al. Presence of CD133-positive circulating tumor cells predicts worse progression-free survival in patients with metastatic castration-sensitive prostate cancer. Int J Urol. 2022;29(5):383–389.
   PubMedGoogle Scholar
• De Laere B, Oeyen S, Mayrhofer M, et al. TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2019;25(6):1766–1773.
   PubMed Web of Science ®Google Scholar
• Chen Z, Wang J, Lu YB, et al. Ezrin expression in circulating tumor cells is a predictor of prostate cancer metastasis. Bioengineered. 2022;13(2):4076–4084.
   PubMed Web of Science ®Google Scholar
• Day KC, Hiles GL, Kozminsky M, et al. HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res. 2017;77(1):74–85.
   PubMed Web of Science ®Google Scholar
• Belic J, Graf R, Bauernhofer T, et al. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving Abiraterone or enzalutamide. Int J Cancer. 2018;143(5):1236–1248.
   PubMed Web of Science ®Google Scholar
• Gong YM, Fan LC, Fei XC, et al. Targeted next-generation sequencing reveals heterogenous genomic features in viscerally metastatic prostate cancer. J Urol. 2021;206(2):280–288.
   Google Scholar
• Fettke H, Kwan EM, Bukczynska P, et al. Prognostic impact of total plasma cell-free DNA concentration in androgen receptor pathway inhibitor-treated metastatic castration-resistant prostate cancer. Eur Urol Focus. 2021;7(6):1287–1291.
   PubMedGoogle Scholar
• Vandekerkhove G, Struss WJ, Annala M, et al. Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer. Eur Urol. 2019;75(4):667–675.
   PubMed Web of Science ®Google Scholar
• Conteduca V, Casadei C, Scarpi E, et al. Baseline plasma tumor DNA (ctDNA) correlates with PSA kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) treated with abiraterone or enzalutamide. Cancers (Basel). 2022;14(9):2219.
   PubMedGoogle Scholar
• Wyatt AW, Annala M, Aggarwal R, et al. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J Natl Cancer Inst. 2018;110(1):djx118.
   Google Scholar
• Tukachinsky H, Madison R, Chung J, et al. Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms. J clin oncol. 2021;39(6_suppl):6.
   Google Scholar
• Cheng HH, Mitchell PS, Kroh EM, et al. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. Plos One. 2013;8(7):e69239.
   PubMed Web of Science ®Google Scholar
• Brase JC, Johannes M, Schlomm T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 2011;128(3):608–616.
   PubMed Web of Science ®Google Scholar
• Bryant RJ, Pawlowski T, Catto JWF, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012;106(4):768–774.
   PubMed Web of Science ®Google Scholar
• Nguyen HCN, Xie WL, Yang M, et al. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate. 2013;73(4):346–354.
   PubMed Web of Science ®Google Scholar
• Gonzales JC, Fink LM, Goodman OB, et al. Comparison of circulating microRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Canc. 2011;9(1):39–45.
   PubMed Web of Science ®Google Scholar
• Zhang HL, Qin XJ, Cao DL, et al. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. Asian J Androl. 2013;15(2):231–235.
   PubMed Web of Science ®Google Scholar
• Bhagirath D, Yang TL, Bucay N, et al. microRNA-1246 is an exosomal biomarker for aggressive prostate cancer. Cancer Res. 2018;78(7):1833–1844.
   PubMed Web of Science ®Google Scholar
• Sharova E, Maruzzo M, Del Bianco P, et al. Prognostic stratification of metastatic prostate cancer patients treated with abiraterone and enzalutamide through an integrated analysis of circulating free microRNAs and clinical parameters. Front Oncol. 2021;11. DOI:10.3389/fonc.2021.626104.
   PubMedGoogle Scholar
• Jiang YM, Zhao H, Chen YX, et al. Exosomal long noncoding RNA HOXD-AS1 promotes prostate cancer metastasis via miR-361-5p/FOXM1 axis. Cell Death Dis. 2021;12(12). DOI:10.1038/s41419-021-04421-0.
   Google Scholar
• Chen LZ, Zhang EC, Guan J, et al. A combined CRISP3 and SPINK1 prognostic grade in eps-urine and establishment of models to predict prognosis of patients with prostate cancer. Front Med-Lausanne. 2022;9: 832415.
   PubMedGoogle Scholar
• Gomez-Cebrian N, Garcia-Flores M, Rubio-Briones J, et al. Targeted metabolomics analyses reveal specific metabolic alterations in high-grade prostate cancer patients. J Proteome Res. 2020;19(10):4082–4092.
   PubMedGoogle Scholar
• Martinez-Pineiro L, Schalken JA, Cabri P, et al. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer. BJU Int. 2014;114(4):608–616.
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Yoon CE, Shin D, et al. Urinary exosome microRNA signatures as a noninvasive prognostic biomarker for prostate cancer. Eur Urol. 2022;81:S1371–S1372.
   Google Scholar
• Li Z, Li LX, Diao YJ, et al. Identification of urinary exosomal miRNAs for the non-invasive diagnosis of prostate cancer. Cancer Manag Res. 2021;13:25–35.
   PubMed Web of Science ®Google Scholar
• Wilkinson KA, Merino EJ, Weeks KM. Selective 2 ‘-hydroxyl acylation analyzed by primer extension (SHAPE): quantitative RNA structure analysis at single nucleotide resolution. Nat Protoc. 2006;1(3):1610–1616.
   PubMed Web of Science ®Google Scholar
• Ramanathan M, Majzoub K, Rao DS, et al. RNA-protein interaction detection in living cells. Nat Methods. 2018;15(3):207–+.
   PubMed Web of Science ®Google Scholar
• Kirk JM, Kim SO, Inoue K, et al. Functional classification of long non-coding RNAs by k-mer content. Nat Genet. 2018;50(10):1474–+.
   PubMed Web of Science ®Google Scholar
• Zhong WB, Wu KH, Long ZN, et al. Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-kappa B-IL6-STAT3 axis. Microbiome. 2022;10(1). DOI:10.1186/s40168-022-01289-w.
   Google Scholar
• Van Poppel H, Roobol MJ, Chapple CR, et al. Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of urology position and recommendations for 2021. Eur Urol. 2021;80(6):703–711.
   PubMedGoogle Scholar
• Wong MC, Goggins WB, Wang HH, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70(5):862–874.
   PubMed Web of Science ®Google Scholar
• Li J, Xu C, Lee HJ, et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature. 2020;580(7801):93–99.
   PubMedGoogle Scholar
• Reichert ZR, Morgan TM, Li G, et al. Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. Ann Oncol. 2023;34(1):111–120.
   PubMed Web of Science ®Google Scholar
• Rasul S, Hartenbach M, Wollenweber T, et al. Prediction of response and survival after standardized treatment with 7400 MBq (177) Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48(5):1650–1657.
   PubMedGoogle Scholar
• Loehr A, Hussain A, Patnaik A, et al. Emergence of BRCA reversion mutations in patients with metastatic castration-resistant prostate cancer after treatment with rucaparib. Eur Urol. 2022;83(3):200–209.
   PubMedGoogle Scholar
• Chung V, Guthrie KA, Pishvaian MJ, et al. Randomized phase II trial of olaparib + pembrolizumab versus olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (g BRCA 1/2+) mutations: SWOG S2001. J clin oncol. 2021;39(3):447–447.
   Google Scholar